906 Participants Needed

PEEP Levels for Premature Birth

(POLAR Trial)

Recruiting at 31 trial locations
DT
LG
Overseen ByLaura Galletta, BSc
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: Murdoch Childrens Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether participants must stop taking their current medications.

What data supports the effectiveness of the treatment Positive End-Expiratory Pressure (PEEP) for premature birth?

Research shows that PEEP, when used in nasal continuous positive airway pressure (CPAP), can reduce the need for more invasive breathing support in very low birth weight infants with breathing problems. However, finding the right PEEP level is crucial, as too little or too much can lead to complications.12345

Is Positive End-Expiratory Pressure (PEEP) generally safe for use in humans?

PEEP is generally used safely in newborns, infants, and children to help with breathing, but it can have complications like lung damage, decreased heart function, and increased pressure in the brain if not set correctly. It is important to tailor PEEP settings individually to minimize risks.12567

How is the treatment PEEP different from other treatments for premature birth?

PEEP (Positive End-Expiratory Pressure) is unique because it helps keep the airways open in premature infants by maintaining a small amount of pressure in the lungs at the end of exhalation, which can improve breathing and gas exchange. Unlike other treatments, PEEP is specifically adjusted to prevent airway collapse and is used immediately after birth to support infants with underdeveloped lungs.12589

What is the purpose of this trial?

Premature babies often need help immediately after birth to open their lungs to air, start breathing and keep their hearts beating. Opening their lungs can be difficult, and once open the under-developed lungs of premature babies will often collapse again between each breath. To prevent this nearly all premature babies receive some form of mechanical respiratory support to aid breathing. Common to all types of respiratory support is the delivery of a treatment called positive end-expiratory pressure, or PEEP. PEEP gives air, or a mixture of air and oxygen, to the lung between each breath to keep the lungs open and stop them collapsing.Currently, clinicians do not have enough evidence on the right amount, or level, of PEEP to give at birth. As a result, doctors around the world give different amounts (or levels) of PEEP to premature babies at birth.In this study, the Investigators will look at 2 different approaches to PEEP to help premature babies during their first breaths at birth. At the moment, the Investigators do not know if one is better than the other. One is to give the same PEEP level to the lungs. The others is to give a high PEEP level at birth when the lungs are hardest to open and then decrease the PEEP later once the lungs are opened and the baby is breathing.Very premature babies have a risk of long-term lung disease (chronic lung disease). The more breathing support a premature baby needs, the more likely the risk of developing chronic lung disease. The Investigators want to find out whether one method of opening the baby's lungs at birth results in them needing less breathing support.This research has been initiated by a group of doctors from Australia, the Netherlands and the USA, all who look after premature babies.

Research Team

DT

David Tingay, MBBS FRACP

Principal Investigator

Royal Children's Hospital

Eligibility Criteria

The POLAR trial is for very premature infants born between 23 and 28 weeks who need help breathing at birth. It's not for babies with severe lung problems, major birth defects, or those whose families decide against aggressive care.

Inclusion Criteria

My newborn needed breathing support right after birth due to being premature.
I have a guardian who can consent to my participation in the study.
My baby was born between 23 and 28 weeks of pregnancy.

Exclusion Criteria

My baby is expected to have severe lung issues due to early water break or fluid buildup.
My legal representative has not agreed to the clinical trial.
Does not have a guardian who can provide informed consent
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Intervention

Dynamic or static PEEP levels are applied to support lung function during resuscitation at birth

20 minutes or until transfer to NICU
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness, including respiratory outcomes and neurodevelopmental assessments

36 weeks PMA

Long-term Follow-up

Assessment of long-term neurodevelopmental and respiratory outcomes

24 months corrected GA

Treatment Details

Interventions

  • Positive End-Expiratory Pressure (PEEP)
Trial Overview This study tests two ways of using PEEP in resuscitation: a constant level versus starting high then lowering it. The goal is to see which method better prevents lung collapse without increasing the risk of chronic lung disease.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Dynamic PEEP GroupExperimental Treatment1 Intervention
Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm. If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O.
Group II: Static PEEP GroupActive Control1 Intervention
Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Murdoch Childrens Research Institute

Lead Sponsor

Trials
90
Recruited
1,303,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborator

Trials
722
Recruited
2,726,000+

University of Oxford

Collaborator

Trials
1,113
Recruited
21,220,000+

Findings from Research

Dynamic airway CT can help determine the optimal PEEP settings for infants with bronchopulmonary dysplasia (BPD) on long-term ventilator support, ensuring at least 50% airway patency.
In a study of 16 infants undergoing 17 CT exams, adjustments to PEEP were made based on CT findings, indicating that this imaging technique may improve management of ventilation in these patients.
A novel approach using volumetric dynamic airway computed tomography to determine positive end-expiratory pressure (PEEP) settings to maintain airway patency in ventilated infants with bronchopulmonary dysplasia.May, LA., Jadhav, SP., Guillerman, RP., et al.[2020]
A systematic review of 11 randomized control trials found no significant difference in hospital, 28-day, or ICU mortality rates between patients with acute respiratory distress syndrome (ARDS) treated with higher versus lower levels of positive end-expiratory pressure (PEEP).
The results indicate that using higher PEEP does not lead to better clinical outcomes in ARDS patients, suggesting that both higher and lower PEEP strategies can be considered safe and effective without a clear advantage for one over the other.
Differential Prognostic Analysis of Higher and Lower PEEP in ARDS Patients: Systematic Review and Meta-Analysis.Liang, M., Chen, X.[2023]
In a study of 18 neurosurgical intensive care patients, applying PEEP at 5 cm H2O did not affect intracranial pressure in those with normal levels, while higher PEEP levels (10 and 15 cm H2O) led to a slight increase in intracranial pressure, but this was not clinically significant as cerebral perfusion pressure remained stable.
For patients with increased intracranial pressure, varying PEEP levels did not significantly alter either intracranial pressure or cerebral perfusion pressure, suggesting that PEEP may be safely used without adverse effects on cerebral hemodynamics in these patients.
Effects of varying levels of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure.McGuire, G., Crossley, D., Richards, J., et al.[2022]

References

A novel approach using volumetric dynamic airway computed tomography to determine positive end-expiratory pressure (PEEP) settings to maintain airway patency in ventilated infants with bronchopulmonary dysplasia. [2020]
Differential Prognostic Analysis of Higher and Lower PEEP in ARDS Patients: Systematic Review and Meta-Analysis. [2023]
Effects of varying levels of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure. [2022]
Application of two different nasal CPAP levels for the treatment of respiratory distress syndrome in preterm infants-"The OPTTIMMAL-Trial"-Optimizing PEEP To The IMMAture Lungs: study protocol of a randomized controlled trial. [2021]
Variation in Positive End-Expiratory Pressure Levels for Mechanically Ventilated Extremely Low Birth Weight Infants. [2019]
Positive end-expiratory pressure during mechanical ventilation and noninvasive respiratory support in newborns and children. [2019]
PEEP and CPAP. [2022]
Positive end-expiratory pressure during resuscitation at birth in very-low birth weight infants: A randomized-controlled pilot trial. [2019]
Neonatal ventilation with a manikin model and two novel PEEP valves without an external gas source. [2017]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security